Clinical significance of 5-fluorouracil chemosensitivity testing in patients with colorectal cancer

10Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Aim: To evaluate whether the results of chemosensitivity testing were associated with prognosis of colorectal cancer patients after adjuvant 5-fluorouracil (FU)/ leucovorin chemotherapy. Patients and Methods: Eighty-nine patients who received 5-FU/leucovorin adjuvant chemotherapy for colorectal cancer were enrolled. Chemosensitivity tests were performed and tumor growth inhibition rate was calculated using the MTT (3-(4,5-dimethylthiazol-2-yl)02,5-diphenyl-2H tetrazolium bromide) assay. Results: Fifty-one patients (57.3%) were sensitive to 5-FU according to the chemosensitivity test. After a median follow-up of 64 months, there was a significant difference between the 5-year disease-free survival rates of the chemosensitive and chemo-resistant groups. However, there was no significant difference in the overall 5-year survival between the chemo-sensitive and chemo-resistant groups. Conclusion: A positive 5-FU sensitivity test with in vitro histoculture drug response assay (HDRA) was associated with better diseasefree survival. Chemosensitivity may be a prognostic factor for colorectal cancer patients undergoing adjuvant 5-FU/ leucovorin chemotherapy.

Cite

CITATION STYLE

APA

Ji, W. B., Um, J. W., Ryu, J. S., Hong, K. D., Kim, J. S., Min, B. W., … Kim, Y. S. (2017). Clinical significance of 5-fluorouracil chemosensitivity testing in patients with colorectal cancer. Anticancer Research, 37(5), 2679–2682. https://doi.org/10.21873/anticanres.11616

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free